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ABSTRACT  
Spontaneous activation enables the complement 
system to respond very rapidly to diverse threats. 
This activation is efficiently suppressed by 
complement factor H (CFH) on self-surfaces but 
not on foreign surfaces. The surface selectivity of 
CFH, a soluble protein containing 20 CCP 
modules (CCPs 1–20), may be compromised by 
disease-linked mutations. However, which of the 
several functions of CFH drives this self-surface 
selectivity remains unknown. To address this, we 
expressed human CFH mutants in Pichia pastoris. 
We found that recombinant I62-CFH (protective 
against age-related macular degeneration) and 
V62-CFH functioned equivalently, matching or 
outperforming plasma-derived CFH, while R53H-
CFH, linked to atypical hemolytic uremic 
syndrome (aHUS), was defective in C3bBb-decay 
accelerating activity (DAA) and factor I-cofactor 
activity (CA). The aHUS-linked CCP-19 mutant 
D1119G-CFH had virtually no CA on (self-like) 
sheep erythrocytes (ES) but retained DAA. The 
aHUS-linked CCP-20 mutant S1191L/V1197A-
CFH (LA-CFH) had dramatically reduced CA on 
ES, but was less compromised in DAA. D1119G-
CFH and LA-CFH both performed poorly at 
preventing complement-mediated hemolysis of ES. 
PspCN, a CFH-binding Streptococcus pneumoniae 
protein domain, binds CFH tightly and increases 
accessibility of CCPs 19–20. PspCN did not 
improve the DAA of any CFH variant on ES. 
Conversely, PspCN boosted the CA, on ES, of I62-
CFH, R53H-FH, and LA-CFH and also enhanced 
hemolysis protection by I62-CFH and LA-CFH. 
We conclude that CCPs 19–20 are critical for 
efficient CA on self-surfaces but less important for 
DAA. Exposing CCPs 19–20 with PspCN and thus 
enhancing CA on self-surfaces may reverse 
deficiencies of some CFH variants.  
 
 
The complement system provides 
antibody-independent first-line immune defense. It 
also augments antibody-mediated and cellular 
immunity (1). In addition, complement contributes 
to clearance of by-products of cellular metabolism 
and cell turnover (2). The cleavage of C3, a 
thioester-containing serum protein, into C3a and 
C3b, is pivotal to all three pathways of 
complement activation. In the alternative pathway, 
C3 is cleaved by C3bBb, a short-lived complex of 
C3b and Bb, a serine protease, In a Mg2+-
dependent process, C3bBb-generated C3b binds to 
complement factor B (CFB), a proenzyme, 
whereupon CFB is cleaved by complement factor 
D (CFD) to yield more C3bBb. Thus a C3b-
amplification loop is generated (3) (Fig. 1A). 
Transiently, nascent C3b can utilize its freshly 
activated thioester to covalently attach to surfaces 
(4). Here, unless regulated, C3b is amplified, 
forms clusters, functions as an opsonin and triggers 
further steps in the complement cascade including 
C5 cleavage, C5a release and formation of 
membrane-attack complexes. 
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A set of plasma proteins calibrates C3b 
amplification. Properdin (5) stabilizes C3bBb 
whereas complement factor H (CFH) (6-8) (Fig. 
1B) destabilizes it – this is called decay-
accelerating activity (DAA). CFH also has 
cofactor activity (CA) for cleavage of C3b by 
complement factor I (CFI). The product, iC3b, 
cannot bind CFB but is an opsonin in its own right 
(9). iC3b may be further degraded to C3dg, and 
ultimately to C3d. C3d(g) remains covalent bound 
to the surface for an extended period of time and 
thereby marks sites of historical complement 
activation and regulation. As a soluble circulating 
complement regulator CFH suppresses 
spontaneous complement activation in fluid phase 
that is considered “futile” and that consumes C3 
and factor B. Critically, CFH efficiently suppresses 
C3b amplification on self surfaces (10) but not on 
foreign ones. Other host complement regulators 
(11), which also exhibit DAA and/or CA, are 
permanently attached to cell-surfaces. Together, 
the complement regulators ensure that the 
opsonising, inflammatory and cytolytic 
consequences of complement activation manifest 
on targets rather than on healthy self-surfaces. 
CFH-related proteins (CFHRs)-1-5 (12) provide 
additional regulatory sophistication. Some of them 
antagonise CFH by competing with it for binding 
to targets including C3b (13,14).  
Inherited variations in membrane cofactor 
protein (MCP, CD46), CFB, C3, CFI, CFHRs and, 
in particular, CFH are linked to diseases (15,16). 
Numerous disease-related sequence variations 
were identified in CFH that consists exclusively of 
20 complement-control protein modules (CCPs). 
The SNP, H402Y, within the seventh CCP (CCP 
7) is linked to age-related macular degeneration 
(AMD) (17-20) and the kidney disorder, C3 
glomerulopathy (C3G) (21); H402 is the at-risk 
allele. The SNP, I62V, in CFH CCP 1 is also 
linked to AMD (20,22); I62 is protective. Deletion 
of the CFHR-1 and CFHR-3 genes decreases the 
risk of immunoglobulin A nephropathy and AMD 
(23-26) but predisposes to systemic lupus 
erythematosus (SLE) and atypical haemolytic 
uraemic syndrome (aHUS), a form of thrombotic 
micoangiopathy leading to end-stage renal failure 
(27). Most mutations found in aHUS patients 
cluster in the CFH C-terminal CCPs 19 and 20 
(28). Other potentially disease-linked sequence 
variations occur elsewhere in CFH (29-31). 
Penetrance is low for many of the CFH 
mutations linked to diseases. Variation in the genes 
for other complement proteins and environmental 
factors may also contribute to disease risk (32). 
The complexity of complement modulation 
underlines the need to explore functional effects of 
each potentially disease-causing CFH variant. 
However, the scarcity of pure CFH samples is 
limiting (22,33). Most patients are heterozygous 
for mutations that occur on a polymorphic 
background. Recombinant production of full-
length CFH, a single polypeptide containing 40 
disulfides (two per CCP) is challenging (34-36). In 
only one case (36) were yields sufficient for 
rigorous sample authentication. 
Many studies tried to recapitulate disease-
linked mutations in more easily produced CFH 
truncations containing up to five CCPs (37-42). 
Indeed, most disease-linked variations occur 
within subsets of CCPs, namely CCPs 1-4, CCP 7 
or CCPs 19 and 20, which coincide with functional 
sites (43) (Fig. 1B). For example, a fragment 
consisting of CFH CCPs 1-4 (CFH 1-4) binds C3b 
and has CA (44) and DAA (45). CFH 19-20 has 
neither CA nor DAA but binds C3b, iC3b and 
C3d(g) (46). Recombinant CFH 6-8 and CFH 19-
20 bind glycosaminoglycans (GAGs) and sialic 
acids (SAs) found on self-surfaces (47). 
Recombinant CFH 19-20 binds well to C3d and 
thereby competes with full-length CFH for binding 
to C3b-decorated sheep erythrocytes (ES) (37), 
while disease-related mutations in CCPs 19-20 
perturbed this ability (39). 
Crucially, the use of small CFH 
truncations cannot capture the collaboration 
between multiple binding sites that characterizes 
CFH function in its biological setting. CFH likely 
undergoes a conformational adjustment (48-50) in 
a concerted process that involves engagement, via 
GAG-binding and SA-binding sites in CCPs 7 and 
20, with self-surface markers (43). This is thought 
to allow the C3b/C3d(g)-binding sites located in 
CCPs 1-4 and CCPs 19-20 (47) to engage 
simultaneously with C3b molecules bound on a 
host surface (50). Crucially, the resultant CFH-
C3b-GAG/SA complex is better at complement 
suppression than the CFH-C3b complex formed on 
a surface lacking GAGs and SAs. Whether this 
enhanced efficacy on self surfaces is driven by 
higher DAA, or higher CA, or both, is unknown. 
Recombinant full-length CFH is needed to 
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investigate these key self versus non-self 
discriminatory properties and to establish the 
phenotypic consequences of disease-related 
mutations. 
Herein we illustrate the value of producing 
recombinant full-length CFH for characterizing 
disease-linked sequence variations. After 
benchmark work on substitutions in N-terminal 
CCPs we focused on more insightful mutations in 
C-terminal CCPs (Fig. 1B). We investigated the 
activities of these CFH mutants on the manmade 
surfaces of surface plasmon resonance (SPR) chips 
and the foreign surface of rabbit erythrocytes (ER) 
as well as on the more host-like surface of ES. We 
additionally investigated the functions of our 
mutants when in complex with PspCN. PspCN is a 
domain from a bacterial complement-evasion 
protein that binds very tightly to CFH (51) and 
causes it to adopt a different conformation with 
enhanced regulatory efficacy (50). Binding to CFH 
of PspCN increases the accessibility of CCPs 19 
and 20, as also likely occurs when CFH binds to a 
self surface. Our studies suggest that CA, more 
than DAA, is boosted by interactions between the 
C-terminal region of CFH and self surfaces. 	
RESULTS  
High-yield production of CFH variants in 
P. pastoris - We produced the two common 
allotypic CFH variants with Ile or Val at position 
62 of the mature protein (I62-CFH or V62-CFH, 
respectively) in recombinant P. pastoris. We also 
produced the disease-related mutants, R53H-CFH 
(on I62 background), D1119G-CFH (on V62 
background) and S1191L/V1197A-CFH 
(henceforth LA-CFH) (on I62 background). The P. 
pastoris-secreted proteins were harvested prior to 
endoglycosidase treatment to cleave mannose-rich 
and hence non-native N-glycans back to the first 
Glc-NAc residues. Following purification, 
homogeneity was assessed using SDS-PAGE (Fig. 
1C). The absence of extra bands in the gel, under 
both reducing and non-reducing conditions, 
indicates minimal proteolytic cleavage. Note that 
cleavage within a CCP might have been evident 
only in reduced samples due to the interlaced 
disulfide bonds within each CCP i.e. Cys(i) to 
Cys(iii) and Cys(ii) to Cys(iv) (52). All proteins were 
prepared in multiple 10-mg quantities. 
V62-CFH and I62–CFH have similar 
biological activities - We compared binding to 
C3b of I62-CFH, V62-CFH and CFH purified 
from human plasma (plasma-CFH). Both 
recombinant protein samples were freshly 
produced, purified and assayed in parallel. The 
plasma-CFH sample was purified from pooled 
human plasma and contained no CFH-related 
proteins detectable by Coomassie blue-stained 
SDS-PAGE (Fig. 1C). Aliquots were stored at -
20 °C. An aliquot was freshly thawed for each 
experiment. The C3b sample (Complement 
Technology, Texas) had been stored at -80° C and 
was also thawed immediately before use. The C3b 
was immobilised on a Biacore C1-sensor chip, 
using amine coupling.  By flowing CFH solutions 
over amine-coupled C3b (Figs. 2A and 2B) we 
obtained similar KD values (in the range of 0.21-
0.33	µM) for all three proteins (Table I). 	
We also compared binding of these three 
versions of CFH to C3d (Complement 
Technology) amine-coupled to a different flow cell 
on the same C1-sensor chip as used for the C3b-
binding experiments (Figs. 2A and 2C). Both I62-
CFH and V62-CFH bound to immobilized C3d 
with KDs of approximately 1.9	 µM (Table I).	
Conversely, binding of plasma-CFH to C3d was, 
as observed previously (13,49,50), too weak to 
measure (Fig. 2A).  The lack of binding between 
plasma-CFH and C3d was previously attributed to 
lack of access to the C3d-binding site in CCPs 19 
and 20. Indeed, premixing 0.6 µM plasma-CFH 
with 1.2-µM PspCN transformed it into a C3d 
binder (Fig. 2D and Table I), as seen previously 
(50). Premixing I62-CFH or V62-CFH with 
PspCN also enhanced their binding to both C3b 
and C3d (Fig. 2D and Table I). For confirmation, 
two additional SPR-based experiments were 
performed on a different batch of I62-CFH, each 
on a different day with a different chip. In both 
experiments (Table I) the KD of I62-CFH for C3b 
was approximately halved	 following pre-
incubation (of I62-CFH) with a twofold molar 
excess of PspCN. Thus both plasma-CFH and 
recombinant CFH bind PspCN, via their central 
CCPs (50), and undergo a conformational change 
that renders the C-terminal modules more 
accessible to C3d. 
In SPR-based assays on a CM5-sensor 
chip (Biacore) we compared abilities of 
recombinant and plasma-CFH to accelerate decay 
of the pre-assembled C3bBb, the alternative 
pathway C3 convertase.  Both I62-CFH and V62-
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CFH, at 20 nM, had identical DAA in this assay, 
while 20 nM plasma-CFH was less active (Fig. 
3A).  The presence of PspCN (at a 2:1 ratio to 
CFH) enhanced the DAA of I62-CFH and V62-
CFH to identical extents (Fig. 3B). As expected, 
PspCN also enhanced the DAA of plasma-CFH in 
this assay.  
Functional similarities between I62-CFH 
and V62-CFH extended to haemolysis-protection 
assays. Upon exposure to increasing percentages 
of CFH-depleted normal human serum (NHS), 
sheep erythrocytes (ES) are susceptible to lysis by 
complement unless protected by added CFH. 
Rabbit erythrocytes (ER), in contrast, lack human-
like sialic acids (SA) and are not effectively 
protected by human CFH. Both I62-CFH and V62-
CFH proved equally effective, e.g. at 250 nM, in 
preventing ES haemolysis (Fig. 4A) in this assay, 
while both were, as expected, equally ineffective, 
at 1	µM, in protecting ER (Fig. 4B). Both I62-CFH 
and V62-CFH showed more ability to prevent ER 
haemolysis when in complex with PspCN. 
In a more specific Es-surface assay (22), 
C3bBb was pre-assembled on ES and the resultant 
C3bBb-decorated cells exposed to a CFH 
concentration series. This was followed by an 
assay of surviving C3bBb, thus allowing 
estimation of an IC50 value for DAA on a “host-
like” cell surface. Both I62-CFH and V62-CFH 
exhibited an IC50 of approximately 1.3 nM in this 
assay (Fig. 5A and Table II). In a related study, ES 
surfaces were preloaded with C3b, and then treated 
with CFI and a CFH concentration series. 
Remaining C3b was estimated in a haemolysis 
assay, as before. This provided an IC50 for the CA 
of CFH on a surrogate self surface. In this assay, 
both I62-CFH (IC50 = 8.0 nM) and V62-CFH (IC50 
= 9.5 nM) had similar potencies (Fig. 5B, Table II).  
The effect of PspCN in both of these assays was 
explored for I62-CFH. Unexpectedly, I62-CFH 
alone and I62-CFH:PspCN complex had 
indistinguishable DAA on ES-bound C3bBb (Fig. 
5C). Conversely, and interestingly, PspCN 
improved the CA of I62-CFH on ES-bound C3b by 
a factor of two (Fig. 5D and Table II).   
In summary, I62-CFH and V62-CFH 
bound with similar affinities to C3b, and to C3d, 
on SPR chips. They had near-identical DAA on 
this manmade “foreign” surface. In haemolysis-
protection assays, both I62-CFH and V62-CFH 
protected self-like ES, but neither protected the less 
self-like ER unless PspCN was present. PspCN 
enhanced binding of both I62-CFH and V62-CFH 
to C3b and C3d on SPR chips, where it also 
enhanced DAA. PspCN increased the CA, but not 
the DAA, of CFH on ES. 
A disease-linked CCP-1 mutation has 
similar effects on self and foreign surfaces - The 
disease-linked R53H mutation in CFH CCP1 was 
previously studied within recombinant CFH 1-4 
(41). While R53H did not perturb binding of C3b 
by CFH 1-4, it did disrupt both the CA and DAA 
of CFH 1-4 on ES. Here we prepared full-length 
R53H-CFH. In side-by-side comparisons R53H-
CFH bound about as tightly as I62-CFH to amine-
coupled C3b. SPR-derived KDs = 1.2 µM for I62-
CFH and 1.8	 µM for R53H-CFH (Fig. 6A and 
Table I) in a first experiment; and 1.0	µM and 1.2 
µM for I62-CFH and R53H-CFH, respectively, in 
a second experiment (Table I). In these two 
experiments, PspCN (2:1 molar ratio to R53-CFH) 
enhanced binding to C3b from 1.8 µM to 1.0 µM, 
or from 1.0 µM to 0.6	µM, respectively. This is a 
similar PspC-induced gain to that seen for I62-
CFH (Table I). 	
Despite their similar affinities for C3b, 
R53H-CFH (at 40 nM) exhibited poorer DAA on a 
CM5-sensor chip (Fig. 6B) in comparison to 40 
nM I62-CFH. Similarly, in assays of DAA 
performed on C3bBb-decorated ES, R53H-CFH 
(IC50 = 6.6 nM) performed less well than I62-CFH 
(IC50 = 1.4 nM) (Fig. 6C, Table II). In an assay on 
C3b-decorated ES, R53H-CFH (IC50 = 43 nM) was 
likewise less effective in CA than I62-CFH (IC50 = 
18 nM) (Fig. 6D). PspCN (2:1 molar ratio to CFH) 
did not noticeably improve the DAA of R53H-
CFH measured on ES (Fig. 6E). A twofold ratio of 
PspCN to R53-CFH did improve its CA on ES (Fig. 
6F and Table II). 
These functional deficiencies of R53H-
CFH were not immediately evident in haemolysis-
protection assays. While R53H-CFH, with or 
without PspCN, did not protect “foreign” ER (Fig. 
4D), it was able to protect the more “self-like” ES 
(Fig. 4C). Protection of ES in this case may reflect 
the inability of R53H-CFH to prevent turnover and 
hence “futile” depletion of C3 in the fluid phase. 
Yet a 1:1 mixture of R53H-CFH with I62-CFH, 
included in an effort to prevent fluid-phase C3 
depletion, was likewise protective in this assay 
(Fig. 4E). By competing with I62-CFH for binding 
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to soluble C3b, R53H-CFH might antagonize the 
fluid-phase C3-conserving regulatory action of 
I62-CFH. In a further investigation of this 
phenomenon, R53H-CFH was mixed 1:1 with the 
S1191L/V1197A-CFH (LA-CFH) mutant. As 
described below, LA-CFH prevents C3 depletion 
in fluid phase even though it exhibits impaired 
binding to SA-decorated surfaces. The R53H-
CFH:LA-CFH mixture was less able to prevent ES 
haemolysis than R53H-CFH alone (Fig. 4E). This 
is consistent with non-depletion of C3, an expected 
consequence of the fluid-phase regulatory action of 
LA-CFH. Importantly, it confirms the lack of 
ability of either LA-CFH or R53-CFH, for 
different reasons, to fully control C3b 
amplification on the ES surface.  
To summarise, R53H-CFH is functionally 
deficient despite retaining good affinity for C3b.  
The inability of R53H-CFH to regulate C3b 
amplification on ES is consistent with its poor ES-
haemolysis-protection properties under 
circumstances where fluid-phase C3 levels are not 
depleted. 
Perturbation of the C-terminal C3b/d-
binding site - Asp1119 of CCP 19 is a key 
interface residue in the CFH 19-20:C3d complex 
(53). In recombinant CFH 19-20, D1119G 
abrogated binding to C3b and C3d (39,53), and 
destroyed the ability to compete with plasma-CFH 
for binding to C3b-decorated ES (37,39). In full-
length CFH, D1119G was previously shown to 
degrade performance in ES haemolysis-protection 
assays (50). To explore further the functional 
consequences of D1119G in full-length CFH, and 
allow comparisons with the other CFH mutants 
reported herein, we measured separately the DAA 
and CA of D1119G-FH on ES. As shown in Figure 
7A and Table II, the ability of D1119G-CFH to 
accelerate decay of C3bBb on ES is diminished 
compared to wild-type CFH (IC50 = 1.3 nM for 
I62-CFH versus IC50 = 11 nM for D1119G-CFH). 
The negative effect of D1119G on the CA of CFH 
for cleavage of C3b bound to ES is greater still 
(IC50 = 12 nM for I62-CFH versus IC50 > 500 nM 
for D1119G-CFH) (Fig. 7B). PspCN (at a 2:1 
molar ratio to D1119G-CFH) had negligible 
effects on the C3bBb-DAA (Fig. 7C) and C3b-CA 
of D1119G-CFH measured on ES (Fig. 7D). 
Perturbation of the sialic acid-binding site 
in CCP 20 - Ser1191 and Val1197 in CCP 20 are 
critical for recognition of SA according to a crystal 
structure of a C3d:CFH 19-20:SA complex (54). In 
previous work, the disease-related double mutation 
S1191L/V1197A perturbed the ability of CFH 19-
20 to compete with full-length CFH for binding to 
C3b-decorated ES (39,53), yet did not perturb the 
structure of CFH 19-20 nor interfere with its 
binding, measured by SPR, to C3b or C3d (42). 
Here, we found that the SPR-measured affinities of 
full-length S1191L/V1197A-CFH (LA-CFH) and 
I62-CFH for amine-coupled C3b are indeed 
similar: KDs = 0.8	µM for LA-CFH versus 1.2	µM 
for I62-CFH in one experiment (Fig. 8A) and 0.9 
µM for LA-CFH versus 1.0	µM for I62-CFH in a 
second experiment (Table I). In these two 
experiments, pre-incubation of LA-CFH with 
PspCN in twofold molar excess produced little if 
any gain in affinity for C3b (KD = 0.70	µM versus 
0.83	 µM; KD = 0.60	 µM	 versus	 0.86	 µM, 
respectively; Table I). No effect of these mutations 
on the DAA of full-length CFH, assayed on the 
SPR chip surface, could be detected (Fig. 8B). 
Taken together, these results suggest the N-
terminal region of	CFH dominates its properties on 
the “foreign” surface of a SPR chip such that C-
terminal mutations have undetectable effects.	
When assayed on host-like ES cells, 
S1191L/V1197A had a smaller effect on DAA 
than on CA (compare Figs. 8C and 8D). The effect 
on DAA was measurable but minor (IC50 = 1.6 nM 
for I62-CFH versus IC50 = 2.9 nM for LA-CFH) 
(Fig. 8C, Table II) while in the CA assays, a larger 
effect was evident (IC50 = 18 nM for IYD-FH 
versus IC50 = 63 nM for S1191L/V1197A-FH) 
(Fig. 8D, Table II). Thus SA binding matters less 
for DAA than it does for CA. Furthermore, we 
found that LA-CFH affords significantly less 
protection than wild-type CFH to ES in the 
haemolysis-protection assay (Fig. 4C). As is 
apparent from the results of further experiments on 
ES, PspCN did not measurably increase the DAA 
of LA-CFH but it clearly enhanced the CA of LA-
CFH (compare Figs. 8E and 8F), although the 
wild-type IC50 was not restored (Table II). In ES 
haemolysis-protection assays, addition of PspCN 
was, notably, able to partially rescue LA-CFH (Fig. 
4C), just as it had previously been found to 
partially rescue another C-terminal mutant, 
D1119G-CFH (50). Moreover, PspCN also 
boosted the ability of LA-CFH to protect the 
“foreign” surface of ER (Fig. 4D). 
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DISCUSSION  
Nearly 100 variations in the human CFH 
gene potentially predispose to aHUS or other 
diseases (16,31). Most encode versions of CFH 
that differ by a single amino acid. Wild-type CFH 
both inhibits fluid-phase C3 consumption and 
prevents formation of clusters of deposited C3b 
molecules on selected surfaces. Only a small 
fraction of the putatively disease-linked versions of 
CFH have been functionally characterized in any 
detail and 75-80% not at all (31). It is often 
impractical to purify sufficient CFH for rigorous 
functional analysis from a heterozygous patient. 
Aiming at a fast and efficient means of obtaining 
10s of mgs of protein, we expressed CFH variants 
in P. pastoris. 
A previously reported careful comparison 
between plasma-purified versions of V62-CFH and 
I62-CFH provided a benchmarking opportunity 
(22). Our yields of recombinant V62-CFH and I62-
CFH exceeded those of previous attempts to 
produce CFH in mammalian (33), insect (34) and 
moss cells (35,55). Our versions of V62-CFH and 
I62-CFH differ in sequence at position 936 as well 
as at position 62 i.e. we compared V62,E936 CFH 
with I62,D936 CFH. The E936D SNP is not 
unique to at-risk or protective haplotypes (20) nor 
located near binding sites (43) for C3b, C3d(g) or 
carbohydrates. While D936 protects against 
susceptibility to meningococcal disease (56), this 
SNP is unlikely to impact on our assays. 
Our recombinant V62-CFH and I62-CFH 
matched functionally our plasma-CFH in our 
assays of C3b binding, DAA and CA (Figs. 2-5). 
Remarkably, though, recombinant V62-CFH and 
I62-CFH bound very much better than plasma-
CFH to immobilized C3d (Fig. 2B). Our pooled 
plasma-derived CFH contains a mixture of 
common haplotypic variants, but these are located 
in CCPs 1, 7 and 15, so are unlikely to impact 
directly on C3d binding that involves only CCPs 
19 and 20. Contamination with CFH-related 
proteins in the plasma-CFH sample is unlikely 
since these were removed during purification. 
While chemical	 modifications may be present in 
ageing plasma proteins (57) these would be 
unlikely to have such a drastic and specific effect. 
The most likely explanation for the difference in 
C3d binding between recombinant CFH and 
plasma-CFH is the lack of N-glycans in 
recombinant CFH.  Natural CFH (36,58) has eight 
of these. Some might contribute to the hidden or 
cryptic nature of the C3d-binding site in CCPs 19-
20 discussed previously (50). 
I62-CFH bound marginally better than 
V62-CFH to C3b in our SPR-based comparison 
using identically prepared samples (Table I), but 
more replicates would be required to afford 
significance to this. In further SPR measurements 
PspCN enhanced C3b binding and the DAA of 
I62-CFH and of V62-CFH to near-identical extents. 
A slightly tighter complex with C3b formed by 
I62-CFH was reported in a SPR study conducted 
on plasma-derived CFH in reverse mode, i.e. C3b 
was flowed over immobilized plasma-CFH (22) 
(KDs; I62, 1.04 µM; V62, 1.33 µM). Comparisons 
of I62 and V62-CFH are important as Ile62 is 
encoded by a SNP unique to a protective haplotype 
for AMD and C3G (20). A “complotype” 
hypothesis (59) predicts that a coincidence of 
minor functional effects in several complement 
proteins could be additive in a patient. Our I62-
CFH versus V62-CFH comparison also agrees 
with the approximate parity of C3b binding 
between recombinant I62 and V62 variants of CFH 
1-4 (41), despite CFH 1-4 binding C3b (KD = 11-
14 µM) much less tightly than full-length CFH. 	
Reported SPR-derived KD values for 
binding of CFH to C3b vary several-fold 
(36,49,53), and the 0.2-0.3	µM KD values obtained 
in our three-way comparison are at the tighter end 
of the range. In other experiments (Table I) we 
obtained weaker KD values, in the 1.0-1.3	 µM 
range, for the same I62-CFH sample. We have, 
over numerous previous experiments, noticed such 
variations between SPR-derived KD values. It 
likely reflects batch-to-batch variations of C3b or 
the sensor chip surfaces. Only measurements made 
on the same chip and in the same experiment can 
be meaningfully compared.   
We mutated another CCP 1 residue 
(R53H) in CFH and compared the consequences 
with those reported for R53H in the autonomously 
functional CFH 1-4 fragment (41,60). We found 
(Fig. 6): (i) near-normal C3b-binding affinity of 
R53H-CFH; (ii) several-fold diminished 
complement-regulatory functions of R53H-CFH 
on ES; (iii) negative impacts of R53H on the DAA 
of CFH on a SPR surface. Encouragingly, these 
benchmark results closely parallel those obtained 
for R53H-CFH 1-4. 
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Such functional deficiencies are consistent 
with R53H causing aHUS (29) although it should 
be borne in mind that patients are heterozygous 
and serum concentrations of CFH are 1-2	µM (61). 
Moreover, 250 nM R53H-CFH had wild-type-like 
protective activity in the CFH-reconstituted Es 
haemolysis assay (Fig. 4). To circumvent a 
potential anomaly of this assay - that fluid-phase 
C3 depletion arises from lack of control by R53H - 
we included along with R53H-CFH equimolar 
amounts of I62-CFH or LA-CFH. I62-CFH 
regulates complement in fluid phase and on 
surfaces; LA-CFH regulates complement in fluid-
phase only (see below). The 1:1 I62-CFH:R53H-
CFH combination, crudely emulating the scenario 
in heterozygous patients, was also protective in our 
assay because adequate I62-CFH was present to 
achieve both fluid-phase and on-surface regulation. 
Conversely, the 1:1 LA-CFH:R53-CFH was not 
protective, demonstrating that 250 nM R53-CFH 
could not protect ES from haemolysis if C3 is 
present in the fluid phase.  
While easily prepared N-terminal 
truncation fragments, such as FH 1-4, serve as a 
good model for full-length CFH, the equivalent 
claim cannot be made for C-terminal fragments. 
More than 30 substitutions in CCPs 19 and 20 
have been linked to aHUS (31). Crosslinking and 
other evidence suggests that the C-terminal CCPs 
of CFH modulate the activities carried out by the 
N-terminal modules of the same molecule (8,50).  
Thus use of full-length CFH is essential to 
characterise functional consequences of mutations 
in CCPs 19 and 20. Aspartate 1119, in CCP 19, is 
a key residue in the C-terminal C3d and C3b-
binding site of CFH (53,62). In the CFH 19-20 
context, an aHUS-linked mutation D1119G (29) 
severely reduced binding to C3d and C3b (39,53). 
Moreover D1119G-CFH 19-20 was 40-fold less 
able than native-sequence CFH 19-20 to compete 
with CFH for binding to C3b-coated ES (39).  We 
previously reported that full-length D1119G-CFH, 
despite having wild-type-like C3b-binding affinity 
and DAA activity on a “foreign” SPR chip surface, 
did not protect ES from haemolysis (50).  Herein 
we have taken this further by showing that 
D1119G diminishes tenfold the ability of CFH to 
accelerate decay of C3bBb assembled on ES. The 
effect of D1119G on the CA of CFH, in the ES 
context, is still greater. 
We further explored this theme through 
studies of the aHUS-linked double mutation in 
CCP 20 of FH corresponding to a gene-conversion 
with CFHR-1, i.e. S1191L/V1197A (63). The 
crystal structure of S1191L-CFH 19-20 bound to 
C3d is barely distinguishable from that of the wild-
type CFH-19-20:C3d complex (42). Conversely, 
LA-CFH 19-20 failed to bind C3b-decorated ES 
(39). Subsequently, S1191 and V1197 were shown 
to contribute to the primary SA-binding site in the 
CFH molecule (54). Here, we found LA-CFH was 
significantly poorer than wild-type CFH at 
protecting ES from haemolysis by CFH-depleted 
normal human serum (Fig. 4). A similar result (see 
above) was obtained using a 1:1 mixture of LA-
CFH and R53-CFH. Yet in SPR experiments the 
S1191L/V1197A substitutions had little impact on 
binding of CFH to C3b. Moreover, these mutations 
had only a small effect on C3bBb-DAA whether 
C3bBb was assembled on an SPR chip surface or, 
surprisingly, on the surrogate host surface of ES 
(Fig. 8). Conversely, LA-CFH was significantly 
deficient in CA on ES cells. This distinction 
between DAA and CA, also seen albeit to a lesser 
extent in D1119G, is discussed further below. 
PspCN binds plasma-CFH tightly, 
enhancing its binding to C3b and strongly 
increasing its affinity for C3d. The C3b/C3d(g)-
binding and self-recognition site in CCPs 19 and 
20 of CFH becomes exposed upon binding PspCN 
(50), perhaps emulating what happens when CFH 
binds to a self-surface. Herein, PspCN enhanced 
affinities for C3b on an SPR chip, of recombinant 
I62-CFH, V62-CFH, R53H-CFH and, to a lesser 
degree, LA-CFH (Table I). PspCN also increased, 
to roughly equal extents, the DAA of I62-CFH and 
V62-CFH on an SPR chip (Fig. 3). In contrast, 
PspCN did not increase the DAA of I62-CFH on 
C3bBb-decorated ES, and there was a similar lack 
of responsiveness to PspCN from R53H-CFH, 
D1119G-CFH and LA-CFH DAA in the ES 
context (Table II). The discrepancy between the 
two assays likely reflects the different surfaces 
employed: SA-bearing and self-like in the case of 
ES; “foreign” in the case of SPR. In contrast with 
its effects on ES-surface DAA, PspCN significantly 
enhanced the CA of I62-CFH on C3b-loaded ES. It 
likewise had a positive effect, in this context, on 
the CA of R53H-CFH, and it even partially 
rescued the CA of LA-CFH (Figure 8). This 
difference between the responsiveness to PspCN of 
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DAA and CA on ES echoes differences between 
the impacts, on DAA (small) and CA (larger), of 
the C-terminal mutations S1191L/V1197A and, to 
a less pronounced extent, D1119G (Table II). 
Both DAA and CA reside in CFH CCPs 1-
4, and can act in a concerted manner, but each 
involves a distinct sequence of events (Fig. 1). To 
accelerate C3bBb decay, CFH probably binds both 
the surface-attached C3b and the Bb (64) 
components of C3bBb, whereupon it acts 
catalytically to dissociate C3bBb into C3b and Bb. 
Following release of Bb, surface-tethered C3b 
retains affinity for CFH because both binding sites 
on C3b, engaged by CFH CCPs 1-4 and CCPs 19-
20, remain intact, as do interactions between CCP 
20 and SA on the surface. The CFH molecule must 
subsequently dissociate from C3b to catalyze 
another C3bBb-decay event. As a cofactor, CFH 
binds to surface-attached C3b and recruits CFI 
(65). Subsequent cleavage of C3b to iC3b destroys 
its binding site for CFH CCPs 1-4 (66). 
Importantly, the binding site on iC3b used by 
CCPs 19 and 20, along with the interaction 
between CCP 20 and SA, is not affected. The 
presence of the product, iC3b or C3d(g), on a SA-
decorated surface thus creates the possibility of 
retaining or enriching CFH on that surface by 
binding to the CFH C-terminus. Thus retained, 
these CFH molecules could utilise their CCPs 1-4 
to act as a cofactor on nearby C3b molecules. In 
short, complete detachment and re-attachment of 
CFH from the surface is likely between cycles of 
DAA; but in the case of CA, CFH can cycle 
between iC3b(C3d)-bound, iC3b(Cd)-plus-C3b-
bound, and C3b-bound forms, without leaving the 
surface. 
The results obtained here for disease-
linked C-terminal mutants on ES surfaces support 
this line of reasoning since they show that 
retention of CFH on a surface via its CCPs 19 and 
20 is more important for CA than for DAA. Our 
results with PspCN likewise support this reasoning 
as they confirm that the PspCN-induced increase 
in access to the surface-engaging C-terminal 
modules has little effect on DAA but a positive 
effect on CA. 
To summarize, our results show that 
acceleration of C3bBb decay on a host-like surface 
is not very responsive to the presence or the 
absence (as tested by mutagenesis (Fig. 8C)), or 
the availability or not (tested by the inclusion or 
not of PspCN (Fig. 8E)), of the self-recognition 
site in CCPs 19 and 20. On the other hand CA (for 
CFI on C3b bound to ES) is sensitive to the 
presence or absence (mutagenesis) of the self-
recognition site  (Fig. 8D) and its availability as 
enhanced by PspCN (Fig. 8F).  
Soluble PspCN has a protective effect on 
ER in haemolysis assays (Fig. 4). This was 
observed previously and is consistent with 
bacterially displayed PspC preventing C3b 
amplification on the microbial surface. PspCN also 
partially rescued functionally deficient LA-CFH in 
an ES haemolysis-protection assay. These are more 
complex assays (compared to the individual CAA 
and DAA assays) and less straightforward to 
interpret. Nonetheless, we infer that PspCN can 
work as a protector of self-surfaces mainly by 
enhancing CFH CA on these surfaces and this 
suggests new therapeutic strategies based on CFH 
activators. 
	
EXPERIMENTAL PROCEDURES 
Preparation of proteins - Human CFH was 
either purchased from Complement Technologies 
(Tyler, TX) or purified from pooled plasma (TCS 
Biosciences Ltd, UK). Other plasma-derived 
human complement proteins (CFB, CFD, CFI, C3b 
and C3d) and CFH-depleted normal human serum, 
from Complement Technologies, were stored as 
recommended by the supplier and used without 
further purification. 
Recombinant human CFH, corresponding 
to allotypic variant, V62,Y402,E936 (V62-CFH), 
was produced and purified, following treatment 
with EndoHf to trim N-glycans to GlcNAc residues, 
as described (36).  Preparation of the D1119G-
CFH mutant (on a V62 background) was described 
previously (50). Similar strategies were used to 
produce variant I62,Y402,D936 (I62-CFH) along 
with R53H-CFH and S1191L/V1197A-CFH on the 
I62 background. In brief, expression-optimized 
DNA encoding the target protein sequence was 
synthesized (GeneArt–Life Technologies) and sub-
cloned into Pichia pastoris expression vector 
pPICZaB (Invitrogen). This was amplified in XL1 
Blu Escherichia coli cells (Agilent) then used to 
transform the KM71H strain of P. pastoris 
(Invitrogen).  Single colonies grown on yeast-
peptone-dextran (YPD) agar plates with 300 µg/ml 
Zeocin were picked. The colony with the highest 
level of CFH production in small-scale trials was 
 at N
ew
castle U
niversity on A
ugust 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Disease-linked mutations in recombinant factor H	
	 9	
used to inoculate a BioFlow 4500 (New Brunswick 
Scientific) ten-litre fermenter. After a glycerol-fed 
batch phase, protein production was induced by a 
four-day methanol-glycerol continuous feed. 
Secreted proteins were chromatographically 
purified (36) after enzymatic deglycosylation.   
The protein PspCN was produced as 
described (50).  In brief, a synthetic gene encoding 
37-140 of PspC from D39 S. pneumoniae was 
expression-optimized for E. coli (GeneArt–Life 
Technologies). It was cloned into E. coli vector 
pE-SumoPro-Kan (LifeSensors, Malvern, PA) then 
expressed in BL21 (DE3) E. coli cells (Lucigen). 
The resultant N-terminally hexaHis-SUMO–
tagged protein was captured on nickel-affinity 
resin, eluted with imidazole then further purified 
by cation-exchange chromatography. The hexaHis-
SUMO tag was cleaved from the fusion protein 
using ULP1, a SUMO-specific protease, and 
removed by re-passing over the nickel-affinity 
resin. Cleaved material was purified by size-
exclusion chromatography. Homogeneity was 
confirmed by SDS-PAGE and mass spectrometry 
(MS). 
Measurement of CFH and CFH:PspCN 
binding to C3b by SPR  - Experiments were 
performed on a Biacore T200 at 25 °C as described 
previously (43). Briefly, C3b was attached using 
standard amine coupling to flow-cells of a Biacore 
C1 chip (GE Healthcare).	A second flow-cell was 
used for background subtraction. A dilution series 
of CFH solutions in 10 mM HEPES buffer, 150 
mM NaCl, 0.05% (v/v) surfactant P20 (GE 
Healthcare), pre-incubated with or without a 
twofold molar excess of PspCN, was injected for 
150 seconds at 50 µl/min and a dissociation time 
of 600 seconds. The sensor chip was regenerated 
by three injections of 1 M NaCl. Data were 
analyzed using the Biacore Evaluation software 
and a 1:1 steady-state binding model. 
C3bBb decay-accelerating assay - Decay-
accelerating activity was measured in an SPR-
based assay as described (67). In brief, ∼500 RU 
of C3b were attached to a Biacore CM5-sensor 
chip (GE Healthcare) using standard amine 
coupling. Subsequently, C3bBb was assembled on 
the chip by a 180-second 10-	µl/min	 injection of 
a solution containing 500 nM CFB and 50 nM 
CFD. Formation of C3bBb (∼150 RU) was 
monitored, then an initial dissociation phase 
(of 240-s duration) allowed observation of 
intrinsic convertase decay i.e. a decline in RUs 
attributable to loss of Bb. Subsequently, CFH or 
CFH:PspCN was injected (10	 µl/min for 180 s), 
allowing observation of a further dissociation 
phase. The chip was regenerated between cycles 
by a 30-s injection of 0.1 µM CFH and three 30-
second injections of 1 M NaCl. 
Preparation of cells for complement 
regulation assays - According to Tortajada et al. 
(22), sheep erythrocytes (ES) in Alsever’s solution 
(TCS Biosciences) were pelleted and re-suspended 
thrice in complement-fixation diluent (C-FxD) 
(Oxoid, Thermo Fisher Scientific). The washed 
cells, at 2% (w/v) in C-FxD, were sensitized by 
incubation with anti-ES stroma antibody from 
rabbit (Sigma) (diluted 1:4000 (v/v) in the C-FxD) 
for 30 minutes at 37 °C. Sensitised sheep 
erythrocytes (EAS) were washed thrice in C-FxD, 
then resuspended in C-FxD to a final cell density 
of 2% (w/v). C3b was then deposited on the EAS 
surface by adding one volume of 4% (v/v) CFB-
deficient and CFH-deficient normal human serum 
(ΔBΔH-NHS (22)) containing 6 µg/ml	
Ornithodoros	 moubata	 complement	 inhibitor	(OMCI)	 (gifted	 by	 Varleigh	 Immuno	Pharmaceuticals)	 in	 C-FxD,	 followed	 by	 20	minutes	incubation	at	37	°C.	The	C3b-coated	EA	(EAS-C3b)	 were	 washed	 thrice	 in	 AP	 buffer	 (5	mM	sodium	barbitone,	pH	7.4,	150	mM	NaCl,	7	mM	MgCl2,	10	mM	EGTA).	Finally,	EAS-C3b	cells	were	re-suspended	at	2%	(v/v),	in	AP	buffer.   
Cofactor assays on erythrocytes - Cofactor 
activity was determined by adding (in triplicate) 50	µl from a dilution series of wild-type or mutant 
CFH solutions, with or without PspCN at a 2:1 
PspCN:CFH molar ratio, to 50 µl of a 2% (w/v) 
suspension of EAS-C3b in AP buffer containing 2.5 
µg/ml FI. After 15 minutes (25 °C) of C3b 
proteolysis, cells were washed thrice in 200 µL of 
AP buffer and pelleted. Washed cells were re-
suspended in 50	 µl AP buffer in preparation for 
C3bBb formation as an indirect measure of 
surviving C3b (22). To this end, C3bBb was 
formed by adding 50 µl of a solution containing 40 
µg/ml CFB and 0.2 µg/ml CFD to 50 µL of the 
CFH-treated and CFI-treated EAS-C3b, and 
incubation for 15 minutes at 37 °C.  Lysis was then 
used as a read-out of C3bBb formed on cells. This 
part of the assay was performed by adding ΔBΔH-
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NHS to a final concentration of 4% (v/v) to the 
suspended cells, and incubation for 20 minutes at 
37 °C. To quantify lysis, cells were pelleted and 
the absorbance (A420 nm) of the supernatant 
measured on a Multiskan Ascent (Agilent). The 
no-lysis controls, for blank subtraction, contained 
no CFB or CFD. Maximal lysis was determined by 
an A420 measurement following the addition of 
PBS, instead of CFH solution, to the EAS-C3b.  
Mean readings from experiments performed in 
triplicate were calculated. Total protection from 
lysis for each concentration of CFH was 
determined by subtracting, from 1, the following: 
[(mean A420 for a particular CFH sample) – (mean 
A420 for a no-lysis control sample)]/[A420 for a 
sample where PBS was used rather than CFH]; 
and then multiplying by 100. A sigmoidal curve 
was fitted using SigmaPlot and employed to 
determine the concentration at which CFH gave 
50% protection from lysis (IC50). 	
Decay-accelerating activities on 
erythrocytes - For these assays, C3bBb was formed 
on EAS-C3b by adding 50 µl AP buffer containing 
40 µg/ml CFB and 0.2 µg/ml CFD to 50 µl of a 
cell suspension (22).  After 15 minutes (37 °C) 
C3bBb formation was stopped by addition of PBS 
containing 250 µM EDTA, pH 7.4 at a 1:20 
dilution. Following addition of 50 µL from a 
dilution series of (wild-type or mutant) CFH 
solutions (with or without PspCN at a 2:1 ratio) in 
PBS, C3bBb was allowed to decay, for 15 minutes 
(25 °C). The extent of lysis then served as a 
measure of remaining C3bBb, as described above. 
As above, mean readings of experiments in 
triplicate were calculated. Total protection from 
lysis for each concentration of CFH was 
determined as above, and a sigmoidal	curve fitted 
using SigmaPlot to determine the	concentration at 
which CFH gave 50% protection from lysis (IC50). 	
Haemolysis-protection assays - For this 
96-well plate assay (46), ES and ER (TCS 
Biosciences) were prepared by washing thrice with 
buffer “E1” (20 mM HEPES, 145 mM NaCl, 0.1% 
(w/v) gelatin (porcine skin, Fluka), 10 mM EDTA, 
pH 7.3) and then buffer “E2” (20 mM HEPES, 145 
mM NaCl, 0.1% (w/v) gelatin, 10	µM EDTA, pH 
7.3). A stock of E was suspended in E2 at a density 
such that an A412 = 1.0-1.2 resulted following 
complete lysis in water. FH-depleted serum (ΔH-
NHS) was reconstituted with a stated, final 
concentration (250 nM - 1.0 µM) CFH, plus or 
minus PspCN (at a 2:1 PspCN:CFH ratio),  and 
then aliquots of varying size were combined, to 
give various percentages of ΔH-NHS/CFH, with 5	
µl E stock and buffer E2 to a final volume of 45 µl. 
Lysis was initiated by adding 5	 µl 50 mM Mg 
EGTA, pH 7.3. The reaction was incubated 
(37 °C) for 30 minute, then quenched with 200 µl 
buffer E1. The plate was spun (1500 g, 10 minutes, 
4 0C) to pellet non-lysed cells, then 100 µl of 
supernatant from each well was transferred to 
another 96-well plate for A412 measurements. 
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FIGURE LEGENDS 
 
FIGURE 1. CFH and its roles in regulating complement. A Amplification of C3b via C3bBb. 
Complement factor H (CFH) accelerates irreversible decay of C3bBb and is a cofactor for complement 
factor I (CFI) that cleaves C3b to iC3b. DAA = decay-accelerating activity; CA = CA. B Schematic of 
CFH highlighting mutations investigated in this study. CFH consists exclusively of 20 complement-
control protein modules (CCPs) shown as ovals. C3b-binding sites (shaded) are located in N-terminal and 
C-terminal regions. The C3b-binding site in CCPs 19-20 also binds iC3b, C3dg and C3d; it is at least 
partially cryptic and is exposed when CFH binds PspCN (P) (a domain from a bacterial virulence factor), 
or when CFH is on a self surface. Self surface-recognition sites, which bind to glycosaminoglycans 
(GAG) and sialic acids (SA), reside in CCPs 7 and 20. CCPs 1-4 are necessary and sufficient (in fluid 
phase) for DAA and CA. C Five deglycosylated recombinant proteins used herein - V62-CFH, I62-CFH, 
R53H-CFH, D1119G-CFH, and S1191L/V1197A-CFH (LA-CFH)  - along with CFH purified from 
pooled plasma were subjected to SDS-PAGE under both reducing (R) and non-reducing (NR) conditions, 
and stained with Coomassie Blue. MW = molecular weight markers. 
 
FIGURE 2. C3b and C3d binding of plasma-purified CFH, I62-CFH and V62-CFH. All data shown here 
were collected in one SPR experiment on the same C1-sensor chip. Care was taken to ensure that the CFH 
samples were all of equivalent quality and concentration. A Twofold dilution series (2.5 µM – 0.019	µM) 
of CFH from plasma were flowed in duplicate over amine-coupled C3b (left panel) or C3d (right panel). 
Equilibrium plots were used in an attempt to estimate KDs (Table I) but no affinity measurement could be 
made for C3d (inset: background-subtracted sensorgrams). B Twofold dilution series (2.5 µM – 0.019	
µM) I62-CFH (left panel) or V62-CFH (right panel) were flowed in duplicate over amine-coupled C3b 
and KDs estimated as above. Two further experiments comparing V62-CFH with plasma-CFH likewise 
indicated similar binding to C3b. C An equivalent set of experiments to (B) but with C3d instead of C3b. 
Multiple replicates confirmed the discrepancy in C3d binding between recombinant-CFH and plasma-
CFH. D Sensorgrams for I62-CFH, V62-CFH, or plasma CFH (p-CFH) all at 0.6	 µM, plus or minus 
PspCN (at 1.2 µM), flowed over C3b (left panel) or C3d (right panel). Very similar PspCN-induced 
enhancements of both plasma-CFH and recombinant CFH binding to C3b and C3d were observed in 
multiple experiments; KD values were estimated for I62-CFH alone versus I62-CFH:PspCN complex (see 
Table I). 
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FIGURE 3. Decay-accelerating activity of CFH on SPR sensor-chips. A C3bBb was formed on a CM5-
sensor chip by flowing C3, complement factor B (CFB) and complement factor D (CFD) over an 
immobilised C3b “seed”. The C3bBb-decay accelerating activities (DAAs) of 20 nM V62-CFH and 20 
nM I62-CFH were compared with that of 20 nM plasma-CFH (p-CFH). B These experiments were 
repeated but with a 1:2 mixture of CFH and PspCN (i.e. CFH:P). The curve for I62-CFH from (A) (i.e. 
with no PspCN) is included for reference; note that I62-CFH and plasma-derived CFH:PspCN (p-CFH:P) 
have overlapping curves. The data shown are representative of an experiment performed four times. 
 
FIGURE 4. Erythrocyte-protection assays. Sheep (ES) or rabbit (ER) erythrocytes were incubated with 
CFH-depleted normal human serum (NHS), at various percentages (v/v), that had been reconstituted with 
our recombinant CFH variants. A Reconstitution with 250 nM I62-CFH or 250 nM V62-CFH afforded 
protection of ES, with or without 500 nM PspCN. B Neither 1 µM I62-CFH nor 1 µM V62-CFH protected 
ER. PspCN (2	µM)	enhances	CFH	protection	in	both	cases.	C	LA-CFH	(500	nM),	unlike	250	nM	I62-CFH,	offered	 little	protection	against	ES	 lysis.	No lysis occurred in the presence of 250 nM R53-CFH. 
The addition of 500 nM PspCN to 250 nM LA-CFH (final concentrations) improved its protective 
properties. D Neither 1 µM LA-CFH (alone) nor 1 µM R53-CFH (± 2 µM PspCN) protected ER, but a 
mixture of 1 µM LA-CFH + 2 µM PspCN was more protective than LA-CFH alone. E LA-CFH (500 nM) 
(unlike 500 nM I62-CFH) did not protect ES from lysis, nor did a mixture of 250 nM LA-CFH + 250 nM 
I62-CFH. A mixture of 250 nM R53H-CFH + 250 nM I62-CFH was protective. A mixture of 250 nM 
R53H-CFH + 250 nM LA-CFH was more protective than 500 nM LA-CFH alone, but less protective than 
R53-CFH alone, see (C). Six independent measurements were made in (B) while (A), and (C-E) are 
representative of two independent experiments. The mean and standard deviation for each measurement 
were calculated for all data sets (in most cases error bars are obscured by the symbol).		
FIGURE 5. Decay-accelerating and cofactor activities of I62-CFH and V62-CFH on ES. A Activated ES 
were preloaded with C3bBb. The C3bBb-decorated cells were exposed to a CFH concentration series, 
followed by a haemolysis-based estimate of remaining C3bBb. This allowed derivation of IC50 values for 
DAA on a “host-like” cell surface. B C3b-preloaded activated ES surfaces were treated with CFI and a 
range of CFH concentrations, providing an estimate of the CA of CFH on a “host-like” cell surface. C The 
DAA assay used in (A) was repeated, but using I62-CFH mixed (1:2) with PspCN. The curve for I62-CFH 
alone is included for comparison. D The CA assay used in (B) was repeated, but using I62-CFH mixed 
(1:2) with PspCN. The curve for I62-CFH alone is included for comparison. The mean and standard 
deviations of triplicate measurements are plotted, and sigmoidal curves were fitted using SigmaPlot. Each 
graph is representative of two experiments, except for (A) and (D) that show data from single experiments.  	
FIGURE 6. Effects	of R53H on CFH. A An SPR experiment was performed in a similar manner to that 
shown in Figure 2(B) to compare the affinity (for immobilized C3b) of R53H-CFH (left panel) with that of 
I62-CFH (right panel; see Expt. 1 in Table I). This experiment was repeated with similar results (see Expt. 
2 in Table I).  B An SPR-based assay of DAA was performed in a similar manner to those shown in Figure 
3 except that 40 nM R53H-CFH or I62-CFH solutions were used. The data shown are representative of 
two experiments. C An ES-based assay of DAA was carried out in a similar manner to that shown in 
Figure 5(A). D An ES-based assay of CA (CA) was carried out in a similar manner to that shown in Figure 
5(B). Triplicate measurements were made for each data point shown in (C) and (D) and each experiments 
was performed once. E In an ES-surface assay, see Figure 5(A), PspCN (mixed 2:1 with R53-CFH) does 
not restore DAA to R53-CFH. F In an ES-surface assay, see Figure 5(B), PspCN at a 2:1 ratio with R53-
CFH enhances its CA. For (C-F), the mean and standard deviations of triplicate measurements are plotted, 
and sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two experiments. 
 
FIGURE 7. On erythrocytes, D1119G-FH has a greater effect on CA than DAA.		In assays similar to the 
one used to generate Figures 5(A) and 5(B), D1119G: (A) decreased the DAA of CFH on ES; and (B) 
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devastated CA on ES. C PspCN (mixed 2:1 with D1119G-CFH) had little effect on the DAA of D1119G-
CFH measured on ES. D PspCN (mixed 2:1 with D1119G-CFH) had a small effect on the very low CA of 
D1119G-CFH measured on ES. Mean and standard deviations of triplicate measurements are plotted, and 
sigmoidal curves were fitted using SigmaPlot. Each graph is representative of two experiments. 
 
FIGURE 8. Effects	 of S1191L/V1197A on CFH. A An SPR experiment was performed in a similar 
manner to that shown in Figure 2(B) to compare the affinity (for immobilized C3b) of LA-CFH (left 
panel) with that of I62-CFH (right panel; see Expt. 1 in Table I). This experiment was repeated with 
similar results (see Expt. 2 in Table I).  B An SPR-based assay of the DAA of LA-CFH was performed in 
a similar manner to those shown in Figure 3 except that 40 nM CFH solutions were used. The data shown 
are representative of two experiments. C An ES-based assay of DAA was carried out in a similar manner 
to that shown in Figure 5(A). D An ES-based assay of CA (CA) was carried out in a similar manner to that 
shown in Figure 5(B). E In an ES-surface assay, see Figure 5(A), PspCN (2:1 to LA-CFH) does not restore 
any DAA to LA-CFH. F Conversely, in an ES-surface assay, see Figure 5(B), PspCN (2:1 to LA-CFH) 
significantly enhanced the CA of LA-CFH. For (C-F), mean and standard deviations of triplicate 
measurements are plotted, and sigmoidal curves were fitted using SigmaPlot. Each graph is representative 
of two experiments. 	 	
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Table	I	Summary	of	SPR	data	
	
EXPERIMENT	 Variant	 Ligand	
	 No	PspCN	 	 														Plus	PspCN 
KD	/	µM
1	 Rmax	 Roffset χ
2	 KD	/µM	 Rmax	 Roffset χ
2	
	 	 	 	 	 	 	 	 	 	 	
I62-CFH	vs.		
V62-CFH	vs.		
plasma-CFH	
I62-CFH	
C3b	
0.21	±	0.02	 79.2	 32.2	 5.2	 	 	 	 	
V62-CFH	 0.27	±	0.03	 80.0	 19.3	 4.6	 	 	 	 	
plasma-CFH	 0.33	±	0.02	 59.6	 8.0	 0.6	 	 	 	 	
I62-CFH	
C3d	
	
1.8	±	0.2	 50.6	 0.5	 0.3	 	 	 	 	
V62-CFH	 2.1	±	0.2	 52.2	 0.0	 0.2	 	 	 	 	
plasma-CFH	 high	 -	 	 -	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	I62-CFH	vs.	
mutants,	+/-	
PspCN	(Expt	1)		
I62-CFH	 	 1.2	±	0.2	 175	 34.8	 5.2	 0.50	±	0.07	 266	 63.5	 31	
R53H-CFH	 C3b	 1.8	±	0.3	 217	 42.9	 6.5	 1.0	±	0.1	 310	 75.3	 13	
LA-CFH	 	 0.83	±	0.10	 181	 46.6	 8.3	 0.70	±	0.07	 249	 91.2	 16	
	 	 	 	 	 	 	 	 	 	 	I62-CFH	vs.	
mutants,	+/-	
PspCN	(Expt	2)		
I62-CFH	 	 1.0	±	0.2	 117	 41.2	 4.0	 0.62	±	0.08	 132	 55.6	 5.8	
R53H-CFH	 C3b	 1.2	±	0.1	 152	 41.1	 3.7	 0.58	±	0.04	 134	 52.1	 2.5	
LA-CFH	 	 0.86	±	0.11	 146	 45.7	 6.6	 0.60	±	0.07	 151	 61.4	 8.0	
	
1	Shown	are	the	standard	errors	for	the	fits	of	the	data	from	each	experiment		 	
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Table	II	Decay	accelerating	and	cofactor	activities	on	sheep	erythrocytes			
Experiment	 CA	
IC50	/	nM
1	
Effect,	on	IC50,	of	
the	variation		
or	(of	PsPCN)2	
DAA	
IC50	/	nM
1	
Effect,	on	IC50,	of	
the	variation		
or	(of	PsPCN)	2	
	 	 	 	 	
I62-CFH	vs	
V62-CFH		
8.00	±	0.33	 1.19	±	0.12	 1.35	±	0.10	 0.94	±	0.11	9.50	±	0.57	 1.27		±	0.05	
	 	 	 	 	I62-CFH	vs	
I62-CFH	+PspCN	
8.00	±	0.33	
3.82	±	0.06	 (0.48	±	0.03)	
1.77	±	0.05	
1.52	±	0.05	 (0.86	±	0.05)	
	 	 	 	 	I62-CFH	vs	
R53H-CFH		
17.5	±	0.8	 2.44	±	0.26	 1.41	±	0.44	 4.72	±	0.32	42.7	±	2.5	 6.65	±	0.25	
	 	 	 	 	R53H-CFH	vs	
R53H-CFH	+	PsPCN	
42.7	±	2.5	
17.2	±	0.6	 (0.40	±	0.04)	
6.68	±	0.6	
6.06	±	0.05	 (0.91	±	0.15)	
	 	 	 	 	I62-CFH	vs	
D1119G-CFH		
12.0	±	0.8	 >40	 1.33	±	0.09	 8.06	±	1.31	>500	 10.7	±	1.05	
	 	 	 	 	D1119G-CFH	vs	
D1119G-CFH	+	PsPCN	
>500	
>500	 -	
9.21	±	0.54	
11.5	±	0.7	 (1.24	±	0.15)	
	 	 	 	 	I62-CFH	vs	
LA-CFH		
17.5	±	2.6	 3.63	±	1.35	 1.59	±	0.06	 1.83	±	0.14	63.4	±	14	 2.92	±	0.12	
	 	 	 	 	LA-CFH	vs	
LA-CFH	+	PsPCN	
63.4	±	14	
47.5	±	13	 (0.75	±	0.38)	
2.23	±	0.16	
1.94	±	0.17	 (0.87	±	0.14)	
	
1	Shown	are	the	standard	errors	for	the	fits	of	the	data	from	each	experiment.	
2	The	ratio	of	either	IC50	for	the	variant/(IC50	for	I62-CFH	or	(IC50	for	CFH	+	PSPCN)	/(IC50	for	CFH	-	
PSPCN).		
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